Favid-06: Phase III, Randomized, Double Blind Placebo-controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin's Lymphoma

Grants and Contracts Details

StatusFinished
Effective start/end date7/9/0410/31/09

Funding

  • Favrille Inc: $17,940.00